<?xml version="1.0" encoding="UTF-8"?><rss xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:atom="http://www.w3.org/2005/Atom" version="2.0"><channel><title><![CDATA[Litmys, LLC]]></title><description><![CDATA[Helping life sciences companies increase the future commercial success of new products through demand driven differentiation]]></description><link>https://www.litmys.com/articles</link><generator>RSS for Node</generator><lastBuildDate>Thu, 05 Nov 2026 11:30:25 GMT</lastBuildDate><atom:link href="https://www.redteamassociates.com/blog-feed.xml" rel="self" type="application/rss+xml"/><item><title><![CDATA[Harris Kaplan Featured on Russo Edge Podcast: Why Approval Isn't the Finish Line]]></title><description><![CDATA[Harris Kaplan joins the Russo Edge podcast to discuss why FDA approval doesn't guarantee adoption and how early commercial planning can improve product potential.]]></description><link>https://www.litmys.com/post/harris-kaplan-featured-on-russo-edge-podcast-why-approval-isn-t-the-finish-line</link><guid isPermaLink="false">6aebbe9c7f6f08d2dd8dd0b3</guid><category><![CDATA[Podcasts]]></category><category><![CDATA[Product Launch]]></category><category><![CDATA[Payer Strategies]]></category><pubDate>Tue, 27 Oct 2026 05:00:00 GMT</pubDate><enclosure url="https://static.wixstatic.com/media/5a8804_3f89fc50384a4e579273885623385279~mv2.png/v1/fit/w_960,h_540,al_c,q_80/file.png" length="0" type="image/png"/><dc:creator>Erin Rooney</dc:creator></item><item><title><![CDATA[Why Product Demand Matters More to PBMs Than Manufacturers Think]]></title><description><![CDATA[Does coverage create demand, or can demand shape coverage? Harris Kaplan explores why strong physician and patient demand may matter more to PBMs than manufacturers realize.]]></description><link>https://www.litmys.com/post/why-product-demand-matters-more-to-pbms-than-manufacturers-think</link><guid isPermaLink="false">6aa977f272df05405686188a</guid><category><![CDATA[Payer Strategies]]></category><category><![CDATA[Product Launch]]></category><category><![CDATA[Marketing]]></category><pubDate>Tue, 15 Sep 2026 17:07:21 GMT</pubDate><enclosure url="https://static.wixstatic.com/media/5a8804_68a53ed4af374787aa75fcfa94c76e6e~mv2.jpg/v1/fit/w_1000,h_1000,al_c,q_80/file.png" length="0" type="image/png"/><dc:creator>Erin Rooney</dc:creator></item><item><title><![CDATA[CAR-T Commercialization Lessons: Insights from the Yescarta Launch]]></title><description><![CDATA[What can the Yescarta launch teach today's life sciences leaders? Building on Harris Kaplan's In Vivo podcast, this article explores the CAR-T commercialization lessons that continue to shape launch strategy, market access, and real-world adoption.]]></description><link>https://www.litmys.com/post/car-t-commercialization-lessons-insights-from-the-yescarta-launch</link><guid isPermaLink="false">6a5fdb07a31281306f0bc72c</guid><category><![CDATA[Product Launch]]></category><category><![CDATA[Oncology]]></category><pubDate>Tue, 21 Jul 2026 05:00:00 GMT</pubDate><enclosure url="https://static.wixstatic.com/media/5a8804_d72a08e8af1b4b679a4aa0e35ab7de2e~mv2.jpg/v1/fit/w_1000,h_1000,al_c,q_80/file.png" length="0" type="image/png"/><dc:creator>Erin Rooney</dc:creator></item><item><title><![CDATA[Harris Kaplan Featured on Citeline's In Vivo Podcast: The Yescarta Launch Examined]]></title><description><![CDATA[What determines whether a breakthrough therapy becomes a commercial success? In this Citeline In Vivo podcast, Harris Kaplan joins former Kite Pharma executive Diane Parks and CAR-T patient Jim Haag to discuss the launch of Yescarta and the critical role that stakeholder adoption, market access, and real-world implementation play in translating scientific innovation into lasting impact.]]></description><link>https://www.litmys.com/post/harris-kaplan-featured-on-citelines-in-vivo-podcast-the-yescarta-launch-examined</link><guid isPermaLink="false">6a32e9c6cf81212a9febbba2</guid><category><![CDATA[Podcasts]]></category><category><![CDATA[Product Launch]]></category><category><![CDATA[Oncology]]></category><pubDate>Wed, 17 Jun 2026 19:06:21 GMT</pubDate><enclosure url="https://static.wixstatic.com/media/5a8804_79bdbcd935534e4c8aac15734e9b6d6d~mv2.png/v1/fit/w_400,h_400,al_c,q_80/file.png" length="0" type="image/png"/><dc:creator>Erin Rooney</dc:creator></item><item><title><![CDATA[Managing Partner, Harris Kaplan, joins industry experts in FirstWord ExpertViews: The Future Impact of the Inflation Reduction Act on Pharma Drug Pricing]]></title><description><![CDATA[The decisions that shape commercial success are increasingly being made long before launch. As the Inflation Reduction Act continues to influence pricing, access, and reimbursement dynamics, companies must consider how evidence generation, differentiation, and value communication fit into their development strategy from the outset. In FirstWord's ExpertViews report, The Future Impact of the Inflation Reduction Act on Pharma Drug Pricing, Harris Kaplan shares his perspective alongside other...]]></description><link>https://www.litmys.com/post/firstword-expertviews-inflation-reduction-act</link><guid isPermaLink="false">6a21ef4914f1bdc71962c31f</guid><category><![CDATA[Product Launch]]></category><category><![CDATA[Payer Strategies]]></category><category><![CDATA[Physicians]]></category><pubDate>Thu, 04 Jun 2026 21:47:11 GMT</pubDate><enclosure url="https://static.wixstatic.com/media/5a8804_bf6787113594408d9b68796f9bf7a609~mv2.jpg/v1/fit/w_1000,h_1000,al_c,q_80/file.png" length="0" type="image/png"/><dc:creator>Erin Rooney</dc:creator></item><item><title><![CDATA[Managing Partner, Harris Kaplan, published in BioSpace: Why KOL Enthusiasm Often Doesn’t Predict Commercial Success]]></title><description><![CDATA[KOL enthusiasm can signal early promise, but it rarely tells the full story. Harris Kaplan examines why expert advocacy often fails to translate into market adoption—and what life sciences teams should evaluate instead.]]></description><link>https://www.litmys.com/post/managing-partner-harris-kaplan-published-in-biospace-why-kol-enthusiasm-often-doesn-t-predict-com</link><guid isPermaLink="false">69e8e930942be5aa10c096de</guid><category><![CDATA[Physicians]]></category><category><![CDATA[KOLs]]></category><category><![CDATA[Marketing]]></category><category><![CDATA[Product Launch]]></category><pubDate>Wed, 22 Apr 2026 15:37:48 GMT</pubDate><enclosure url="https://static.wixstatic.com/media/5a8804_192c430fc1ee461cbcad98caebeb0cc7~mv2.jpg/v1/fit/w_1000,h_1000,al_c,q_80/file.png" length="0" type="image/png"/><dc:creator>Erin Rooney</dc:creator></item><item><title><![CDATA[Regulatory Uncertainty in Life Sciences Is Increasing the Risk of Innovation]]></title><description><![CDATA[Innovation in life sciences has always involved uncertainty. Today, however, regulatory unpredictability is becoming a growing driver of risk, influencing not only approval pathways but also real world confidence in new therapies.]]></description><link>https://www.litmys.com/post/regulatory-uncertainty-in-life-sciences-is-increasing-the-risk-of-innovation</link><guid isPermaLink="false">6996428d7b02767d86629369</guid><category><![CDATA[Product Launch]]></category><pubDate>Wed, 18 Feb 2026 23:07:18 GMT</pubDate><enclosure url="https://static.wixstatic.com/media/5a8804_69c239708a1641bcbbb711d9f8e9588a~mv2.jpg/v1/fit/w_1000,h_1000,al_c,q_80/file.png" length="0" type="image/png"/><dc:creator>Erin Rooney</dc:creator></item><item><title><![CDATA[Managing Partner, Harris Kaplan, published in PharmExec: Your Phase III Clinical Protocol Is Your Initial Product Launch]]></title><description><![CDATA[Phase III clinical protocols do more than satisfy regulators. They determine what a product can claim, how it will be valued, and whether it can truly compete at launch. ]]></description><link>https://www.litmys.com/post/phase-iii-is-is-your-initial-launch</link><guid isPermaLink="false">698103ed889819a51f051bf3</guid><category><![CDATA[Product Launch]]></category><category><![CDATA[Phase III]]></category><pubDate>Fri, 30 Jan 2026 20:19:53 GMT</pubDate><enclosure url="https://static.wixstatic.com/media/5a8804_f8a9f11cd22f40eabfa4bc85188b6199~mv2.jpg/v1/fit/w_1000,h_1000,al_c,q_80/file.png" length="0" type="image/png"/><dc:creator>Erin Rooney</dc:creator></item><item><title><![CDATA[Webinar on Demand: Why the Battle for Future Market Share is Increasingly Won Before Phase 3]]></title><description><![CDATA[Most products that stumble post-approval don’t fail on efficacy; they fail because they weren’t built with the market in mind. Our recent webinar, Why the Battle for Future Market Share is Increasingly Won Before Phase 3, brought together experts from across biotech, investment, clinical, and pharma to discuss how to design for adoption, not just approval.]]></description><link>https://www.litmys.com/post/webinar-on-demand-why-the-battle-for-future-market-share-is-increasingly-won-before-p</link><guid isPermaLink="false">68daf18564e88a07d0789dad</guid><category><![CDATA[Webinars]]></category><pubDate>Mon, 29 Sep 2025 22:03:11 GMT</pubDate><enclosure url="https://static.wixstatic.com/media/5a8804_fd548023f14b47b8b4d1f53f8e65ef54~mv2.png/v1/fit/w_940,h_705,al_c,q_80/file.png" length="0" type="image/png"/><dc:creator>Erin Rooney</dc:creator></item><item><title><![CDATA[Managing Partner, Harris Kaplan, published in In Vivo: Physician Behavioral Inertia - Innovation’s Greatest Enemy]]></title><description><![CDATA[Harris Kaplan , Managing Partner, just published an article in In Vivo,  Physician Behavioral Inertia: Innovation’s Greatest Enemy ....]]></description><link>https://www.litmys.com/post/physician-behavioral-inertia</link><guid isPermaLink="false">68a3b57b257a53432c926b50</guid><category><![CDATA[Physicians]]></category><pubDate>Tue, 26 Sep 2023 05:00:00 GMT</pubDate><enclosure url="https://static.wixstatic.com/media/5a8804_f848b759469e4cbb9b7e603e97082720~mv2.jpg/v1/fit/w_1000,h_1000,al_c,q_80/file.png" length="0" type="image/png"/><dc:creator>Erin Rooney</dc:creator></item><item><title><![CDATA[Managing Partner, Harris Kaplan, published in Forbes: Biotech Investing - Is Hope Fueling Hype?]]></title><description><![CDATA[Harris Kaplan , Managing Partner, just published an article in Forbes,  Biotech Investing: Is Hope Fueling Hype? . Hope is a major reason...]]></description><link>https://www.litmys.com/post/biotech-investing-is-hope-fueling-hype</link><guid isPermaLink="false">68a3b4286aa481be493156d6</guid><category><![CDATA[Investing]]></category><pubDate>Thu, 28 Oct 2021 05:00:00 GMT</pubDate><enclosure url="https://static.wixstatic.com/media/5a8804_0131b69202ba4bb6aa99a6e7d38a8084~mv2.jpg/v1/fit/w_800,h_304,al_c,q_80/file.png" length="0" type="image/png"/><dc:creator>Erin Rooney</dc:creator></item><item><title><![CDATA[Managing Partner, Harris Kaplan, published in Forbes: The Importance Of Being An Optimistic Realist In Biotech Investing]]></title><description><![CDATA[Harris Kaplan , Managing Partner, just published an article in Forbes,  The Importance Of Being An Optimistic Realist In Biotech...]]></description><link>https://www.litmys.com/post/optimistic-realist-in-biotech-investing</link><guid isPermaLink="false">68a3b13034b07f0731c510f6</guid><category><![CDATA[Investing]]></category><pubDate>Tue, 13 Jul 2021 05:00:00 GMT</pubDate><enclosure url="https://static.wixstatic.com/media/5a8804_466c2fcebf0447dcba00333fd2e10017~mv2.png/v1/fit/w_1000,h_1000,al_c,q_80/file.png" length="0" type="image/png"/><dc:creator>Erin Rooney</dc:creator></item><item><title><![CDATA[Managing Partner, Harris Kaplan, published in PM360: Into the Mind of the Payer]]></title><description><![CDATA[Harris Kaplan , Managing Partner, just published an article on PM360,  Into the Mind of the Payer . Harris has interviewed countless...]]></description><link>https://www.litmys.com/post/into-the-mind-of-the-payer</link><guid isPermaLink="false">68a3b00534b07f0731c50e60</guid><category><![CDATA[Payer Strategies]]></category><pubDate>Mon, 26 Apr 2021 05:00:00 GMT</pubDate><enclosure url="https://static.wixstatic.com/media/5a8804_9d89e5b723ed4876bc22a1c2caf20e4a~mv2.png/v1/fit/w_1000,h_1000,al_c,q_80/file.png" length="0" type="image/png"/><dc:creator>Erin Rooney</dc:creator></item><item><title><![CDATA[Managing Partner, Harris Kaplan, published in Forbes: All That Glitters Isn't Gold: Questions To Ask ]]></title><description><![CDATA[Harris Kaplan , Managing Partner, just published an article in Forbes,  All That Glitters Isn't Gold: Questions To Ask Yourself Before...]]></description><link>https://www.litmys.com/post/all-that-glitters-isnt-gold</link><guid isPermaLink="false">68a3af0c34b07f0731c50c23</guid><category><![CDATA[Investing]]></category><pubDate>Wed, 10 Mar 2021 06:00:00 GMT</pubDate><enclosure url="https://static.wixstatic.com/media/5a8804_0478da84a46148f3b56884dcd5a987b9~mv2.jpg/v1/fit/w_1000,h_1000,al_c,q_80/file.png" length="0" type="image/png"/><dc:creator>Erin Rooney</dc:creator></item><item><title><![CDATA[Managing Partner, Harris Kaplan, published in PharmExec: Marketers - Physicians are People First]]></title><description><![CDATA[Harris Kaplan , Managing Partner, just published an article in PharmExec (titled  Marketers: Physicians are People First ) that looks at...]]></description><link>https://www.litmys.com/post/marketers-physicians-are-people-first</link><guid isPermaLink="false">68a3b31e81e6ee2fae5be21b</guid><category><![CDATA[Marketing]]></category><category><![CDATA[Physicians]]></category><pubDate>Tue, 17 Nov 2020 06:00:00 GMT</pubDate><enclosure url="https://static.wixstatic.com/media/5a8804_bc4475945bb84e35920f8d4e47876cd4~mv2.png/v1/fit/w_1000,h_845,al_c,q_80/file.png" length="0" type="image/png"/><dc:creator>Erin Rooney</dc:creator></item><item><title><![CDATA[Join us for Informa’s Newest Webinar – Transforming Cancer Treatment with Early Detection Diagnostics: Opportunities and Obstacles]]></title><description><![CDATA[We are pleased to announce that on October 22, Managing Partner,  Harris Kaplan , will be joined by experts in the oncology field, where...]]></description><link>https://www.litmys.com/post/join-us-for-informa-s-newest-webinar-transforming-cancer-treatment-with-early-detection-diagnostic</link><guid isPermaLink="false">68a3acd06aa481be493145c6</guid><category><![CDATA[Oncology]]></category><category><![CDATA[Outcomes]]></category><category><![CDATA[Webinars]]></category><pubDate>Thu, 01 Oct 2020 05:00:00 GMT</pubDate><enclosure url="https://static.wixstatic.com/media/5a8804_819f06c1915f4d9f86749d59e77e7d9b~mv2.jpg/v1/fit/w_991,h_759,al_c,q_80/file.png" length="0" type="image/png"/><dc:creator>Erin Rooney</dc:creator></item><item><title><![CDATA[Virtual Health Care: Where Does This Leave Pharma Marketing?]]></title><description><![CDATA[Managing partner,  Harris Kaplan , participated in  Pharma intelligence ‘s 24-hour web event on  COVID-19: Lessons Learned and a Path...]]></description><link>https://www.litmys.com/post/virtual-health-care-where-does-this-leave-pharma-marketing-1</link><guid isPermaLink="false">68a3ab966aa481be49314246</guid><category><![CDATA[Marketing]]></category><pubDate>Tue, 01 Sep 2020 05:00:00 GMT</pubDate><enclosure url="https://static.wixstatic.com/media/5a8804_4d07033d3b784b05abb1a453dd1d9100~mv2.jpg/v1/fit/w_790,h_444,al_c,q_80/file.png" length="0" type="image/png"/><dc:creator>Erin Rooney</dc:creator></item><item><title><![CDATA[Join us for Informa’s 24-Hour Web Event – COVID-19: Lesson Learned and a Path Forward]]></title><description><![CDATA[We are pleased to announce that  Harris Kaplan , Managing Partner, will be participating in a new  24-hour web event , hosted by  Informa...]]></description><link>https://www.litmys.com/post/join-us-for-informa-s-24-hour-web-event-covid-19-lesson-learned-and-a-path-forward</link><guid isPermaLink="false">68a3aa2e054d02f5f63b760a</guid><category><![CDATA[Marketing]]></category><category><![CDATA[Webinars]]></category><pubDate>Wed, 01 Jul 2020 05:00:00 GMT</pubDate><enclosure url="https://static.wixstatic.com/media/5a8804_b9f7896b2afc457c9d7b52211b75b05e~mv2.jpg/v1/fit/w_962,h_759,al_c,q_80/file.png" length="0" type="image/png"/><dc:creator>Erin Rooney</dc:creator></item><item><title><![CDATA[Payer Power: What Are The Future Implications For Life Science Companies Developing New Products?]]></title><description><![CDATA[Harris Kaplan , Managing Partner, has partnered with  Fred Dotzler  to write the cover story for In Vivo January 2019.  The article delves into what payers are doing in today’s world to try to control the cost of new life science products, and what steps they plan on taking to better control rising costs in the future. Payer Power: What Are The Future Implications For Life Science Companies Developing New Products?]]></description><link>https://www.litmys.com/post/payer-power</link><guid isPermaLink="false">68a39cc847dd002d68d4312b</guid><category><![CDATA[Payer Strategies]]></category><category><![CDATA[Marketing]]></category><pubDate>Wed, 16 Jan 2019 06:00:00 GMT</pubDate><enclosure url="https://static.wixstatic.com/media/5a8804_58ac3201ba27408fa8e28b28531bf80e~mv2.jpg/v1/fit/w_652,h_840,al_c,q_80/file.png" length="0" type="image/png"/><dc:creator>Erin Rooney</dc:creator></item></channel></rss>